Beginner's Mind

Beginner's Mind

Download on the App Store

All Beginner's Mind episodes

  • #31: This was 2020 - A Year in Review

    What was hot and what not - in Blockchain and Life Science and other Tech Areas the speakers love.

    Listen about what was going on in the world in 2020 - besides SARS CoV 2.

    Speaker:
    Albert Missbichler (https://www.linkedin.com/in/albert-missbichler-3a362931/)
    Astrid Woollard (https://www.linkedin.com/in/astridwoollard/)
    Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
    Elisabeth Pfneisl (https://www.linkedin.com/in/elisabeth-pfneisl-81095163/)
    Gregory Mannix (https://www.linkedin.com/in/greg-mannix/)
    Irina Korschineck (https://www.linkedin.com/in/irina-korschineck-35a40289/)
    Jama Nateqi (https://www.linkedin.com/in/jama-nateqi/)
    Julia Resch (https://www.linkedin.com/in/julia-resch/)
    Kimberly Cornfield (https://www.linkedin.com/in/kimberly-cornfield-55383136/)
    Klara Brandstätter (https://www.linkedin.com/in/klara-brandst%C3%A4tter-b6029491/)
    Matthias Tarasiewicz (https://www.linkedin.com/in/parasew/)
    Michael Browne (https://www.linkedin.com/in/michael-browne-frsa-5a616138/)
    Thomas Schirrmann (https://www.linkedin.com/in/thomas-schirrmann-45a64183/)

    Organizations:
    Corat Therapeutics (https://www.linkedin.com/company/corat-therapeutics/)
    CS Life Science Invest (https://lnkd.in/eyhWK7H)
    Crowdhelix (https://www.linkedin.com/company/crowdhelix/)
    Falcon Digital Investment (https://www.linkedin.com/company/falcon-digital-investments/about/)
    Fianostics (https://www.fianostics.at/en/home/)
    IECT Hermann Hauser (https://www.linkedin.com/company/iect-hermann-hauser)
    Ingenetix (https://www.ingenetix.com/en/home/)
    Life Science Nation (https://www.linkedin.com/company/life-science-nation/)
    RIAT - Research Institute for Future Cryptoeconomics  (https://riat.at/)
    Symptoma (https://www.linkedin.com/company/symptoma/)
    UCL (https://www.linkedin.com/school/university-college-london/)
    Vienna Stock Exchange (https://www.linkedin.com/company/wiener-borse-ag/)
    Yumab (https://www.linkedin.com/company/yumab-gmbh/)


    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    3 hr 5 min
  • #30: Alexander Wurzer - The Digital Shift: Navigating the Complex World of Digital Patents

    In the age of Industry 4.0, as businesses pivot towards digitization, the landscape of intellectual property rights is evolving rapidly. How can companies stay ahead in this game of digital patents?

    Dive into this episode to uncover:

    • The challenges and intricacies of patenting digital business models.
    • The shift from traditional patent perspectives to a software-driven economy.
    • The role of intellectual property in safeguarding and innovating digital business strategies.

     About Prof. Alexander Wurzer:
    A renowned expert in the field of intellectual property, Prof. Alexander Wurzer delves deep into the complexities of digital patents. With extensive experience and insights, he sheds light on the changing dynamics of the digital age and its implications on business models and strategies.

    Key Quotes:
    (04:14) "Europe is not really represented in patent applications for digital fields."
    (18:03) "It's not about reality; it's a game. As long as you fulfill the legal provisions, you'll get your patent."
    (32:00) "Only ownership gives me the right to motivate a third party to use that estate."
    (49:15) "As soon as you explain the implementation, it transitions from an idea to something patentable."
    (1:03:58) "This person should fall in love with your idea and passionately fight for it."
    (1:27:43) "When you are natural born in the cloud, you write different patents and use the patent in a totally different way like you make software; you understand the concepts, the architecture, the implementation."

    Timestamps:
    (0:12) Exploring the Patentability of Digital Business Models
    (1:25) The Evolution of Digital Patent Perspectives
    (4:14) The Reality of Patenting Digital Business Models in Europe
    (14:55) Technological Knowledge vs. Real-World Application
    (18:03) The Game of Patents: Reality vs. Possibility
    (25:00) Leveraging Patents in the Digital Age
    (30:49) The Misunderstanding of Open Source and Patents
    (34:06) The Intricacies of Digital Business Models and Patents
    (42:49) Why Global Companies Enforce Digital Patents in Germany
    (46:39) Formulating Technical Solutions in Patents
    (49:15) The Fine Line Between Ideas and Patentable Implementations
    (57:54) Starting with Business Cornerstones for Patenting
    (1:02:22) The Essence of Combining Life Science and Digital Expertise
    (1:03:22) Emotional Connection: The Key to Patent Success
    (1:07:41) Strategies Behind Patenting: Beyond Just Granting
    (1:33:24) Rethinking the Purpose: Clean Clothes over Washing Machines
    (1:34:58) Tesla's Vision: Beyond Cars to Realizing Use Cases
    (1:41:12) IP Strategy: Balancing Trade Secrets and Patents



    For the videophile:
    The Video to the Podcast

    Speaker:
    Prof. Alexander Wurzer (https://www.linkedin.com/in/profalexanderwurzer/)
    Astrid Woollard (https://www.linkedin.com/in/astridwoollard/)
    Christian Soschner (https://www.linkedin.com/in/christiansoschner/)

    Organizations:
    CS Life Science Invest (https://lnkd.in/eyhWK7H)
    IP Business Academy (https://www.linkedin.com/company/ipbusinessacademy/)

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 51 min
  • #29: Ultraleap. Digital Worlds that Feel Human.


    One problem in the digital world is: We cannot feel the interaction.

    Prof. Sriram Subramanian is working on solutions for this problem. He has spun out Ultraleap from the University of Bristol. The company translates the research into products for the digital world.

    In this episode, I will talk with Prof. Subramanian about real-life applications for his inventions, the importance of touch for well-being, and the potential for the life science industry.

    Speaker:
    Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
    Sriram Subramanian  (https://www.linkedin.com/in/srisub/)

    Organizations:
    CS Life Science Invest (https://lnkd.in/eyhWK7H)
    UCL (https://www.linkedin.com/school/university-college-london/)
    Ultraleap   (https://www.linkedin.com/company/ultraleap/)

    Timestamps:

     (00:00:00) Sriram Subramanian on Ultraleap, touchless tech, and digital worlds that feel human
     (00:01:29) What mid-air haptics is: creating the sense of touch with ultrasound
     (00:04:24) From UCL student project to Ultraleap spinout: how the company started
     (00:07:01) Building a deep-tech company: IP negotiations, capital, and early customer pressure
     (00:10:25) “Fundraising never stops”: the real financing lesson behind scientific spinouts
     (00:12:24) Why the pandemic made touchless interfaces suddenly urgent
     (00:14:23) How touchless kiosks work in supermarkets, ATMs, and public machines
     (00:16:17) Beyond Minority Report: how tactile feedback makes touchless interfaces usable
     (00:17:51) Acoustic levitation explained: floating objects in air and building real holograms
     (00:22:01) Touchable holograms, digital hugs, and the future of human connection online
     (00:29:46) Life science use cases: drug delivery, predator-prey research, and acoustic control
     (00:36:20) Telemedicine and remote surgery: can doctors one day feel holograms?
     (00:46:26) Virtual conferences, trust, and the missing magic of serendipitous networking
     (00:49:34) The next big challenge: scaling holograms and making the tech mass-producible
     (00:52:04) Advice to scientific entrepreneurs: use the university as a soft landing and take risks 



    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    59 min
  • #28: Daniela Marino: How Cutiss Raised CHF 20M in 7.5 Weeks After Its Lead Investors Walked Away

    March 2020. Cutiss was in the middle of its Series B when the lead investors pulled out. Asian funds stopped leading deals in Europe. US funds would not back a Swiss company at the center of Europe's outbreak. The cash would last until 1 October.

    Daniela Marino, co-founder and CEO of Cutiss AG in Zurich, flipped the plan. She wrote her own term sheet and went to Swiss private investors and family offices. She pitched from home with her kids in the background, up to 12 times in one day. One investor told her the pitch beat watching a movie. Seven and a half weeks later, the round closed at CHF 20 million (Swiss francs).

    Cutiss grows personalized skin grafts from a small biopsy of the patient's own skin. The first target is severe burns, where patients often lack enough healthy skin to harvest and live with painful scars for years.

    In this episode you will hear:
    - How a free business course in the south of France turned a postdoc into a CEO in one week
    - Why she took three years to go from idea to incorporation
    - How skin is grown from a biopsy and why the patient becomes "the last bioreactor"
    - What to do when your fundraising plan collapses mid-round
    - Why a non-COVID story stood out to investors in 2020
    - Why Asia leads in regenerative medicine
    - Her advice for scientists who want to run a company

    CHAPTERS

    From scientist to founder
    (00:00) Intro: Switzerland and Austria in the second wave
    (00:52) Becoming an entrepreneur "overnight"
    (03:23) The pitch competition in Sophia Antipolis
    (06:25) Three years from idea to company
    (11:08) What the name Cutiss means

    The science
    (11:53) Skin on demand: the business model
    (14:22) How the skin is grown
    (16:11) Burns, donor-site shortage and scarring
    (19:08) Where regenerative medicine is heading

    The fundraise
    (21:48) Closing CHF 20M during the pandemic
    (29:27) Where the money goes
    (31:20) Pitching a non-COVID story in 2020
    (35:26) Building a new category and finding partners
    (39:09) Why Asia is ahead

    Lessons for founders
    (41:04) Advice for scientists who want to be CEO
    (48:26) Staying positive through bad days
    (52:22) The 2020 lesson: resilience and granular milestones

    GUEST
    Daniela Marino
    Cutiss AG:

    HOST
    Christian Soschner: 

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    56 min
  • #27: How to Find Your Vision and Passion for Founding a Company


    In the last episodes, I have talked with investors and decision-makers of the pharmaceutical industry about the importance of having a vision and passion for the life science company.

    I want to explore this topic further and ask the life science entrepreneur Christof Goetz to chat with me about finding your vision and passion for your company.

    Christof is a Serial Entrepreneur with more than 20 years of experience managing complex business, software, and hardware development projects. 

    MyMind is a life science company based in Vienna. MyMinds vision is to help people with neurological impairments to live towards their full brain potential with affordable and easy-to-use brain training and assessment technology. MyMind currently focuses on Autism Spectrum Disorders (ASD), whether comorbid with Attention Deficit Hyperactivity Disorder (ADHD), Intellectual Disability (low IQ), Epilepsy, and Anxiety. Subsequently, MyMind will extend to other neurological issues such as dementia or stroke recovery.


    Speaker:
    Christof Goetz (https://www.linkedin.com/in/christofgoetz/)
    Christian Soschner (https://www.linkedin.com/in/christiansoschner/)

    Organizations:
    CS Life Science Invest (https://lnkd.in/eyhWK7H)
    My Mind GmbH (https://www.linkedin.com/company/mymindvienna/)

    Be part of our Network:
    Subscribe here:  https://mailchi.mp/e2467061ef75/lsg2g

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 1 min
  • #26: Science Explained - PCR Tests for Dummies

    In this episode, I had the pleasure of talking with two Diagnostics Experts.

    Irina Korschinek, CEO of Ingenetix and Albert Missbichler, Business Angel specialized in Diagnostics.

    Do you want to know answers to all or one of the following questions?

    • What is a PCR test?
    • Why is it the gold standard for measuring SARS-Cov2 Infections?
    • What does a positive or negative test result say?
    • Why do false positives and false negatives exist. Shouldn`t the test have 100% accuracy?
    • Why do no yes or no answers exist to a viral infection?
    • What makes diagnostics so complex?

    Speaker:
    Albert Missbichler (https://www.linkedin.com/in/albert-missbichler-3a362931/
    Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
    Irina Korschinek (https://www.linkedin.com/in/irina-korschineck-35a40289/)

    Organizations:
    CS Life Science Invest (https://lnkd.in/eyhWK7H)
    Ingenetix (https://www.ingenetix.com/en/home/)
    Fianostics (https://www.fianostics.at/en/home/)

    Be part of our Network:
    Subscribe here:  https://mailchi.mp/e2467061ef75/lsg2g

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    57 min
  • #25: Karel Kubias - What Is the Secret to Successful Tech Transfer?

    Did you know that the successful pipeline of one of the most important pharmaceutical companies in the United States started in Europe, and scientists from Prague played a key role? Did you know that profound expertise in turning deep tech life science into a business, scale it, and go public in the US can be found in Prague since the late 80s of the previous century?

    If you want to know which US pharmaceutical companies' pipeline started in Prague, then listen to this Episode Number 25. I am delighted to host an exceptional guest from one of the most beautiful cities in Europe. I will talk with Karel Kubias from  i&i in Prague.

    Karel studied organic chemistry and photochemistry at TH Merseburg, Germany, and holds an MBA in Healthcare Management (Auburn University program).

    He gained his broad professional knowledge and skills during his 24 years in various management positions at multinational chemical and pharmaceutical company Merck KGaA. Between 2006 – 2015, Karel worked in executive positions – first as Managing Director of Merck spol. s r.o.. Prague and then as Regional sales director for the region EEMEA (Eastern Europe, Middle East & Africa) of Merck Millipore division, where he acquired further experience on the international level. He now supports i&i Prague as Director for Partnerships and Strategic Alliances.

    i&i Prague is accelerating the proof-of-concept stage of projects in the fields of Medtech, Diagnostics, and Drug discovery. The company focuses on projects in the discovery, pre-seed, or seed phase with excellent innovative potential, which will benefit from the project-launching experience and networking skills developed by IOCB Tech over the last decade. Furthermore, the financial support provided by i&i Prague should significantly increase the appeal and value of a project for further licensees and/ or investors.

    Youtube

    Speaker:
    Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
    Karel Kubias (https://www.linkedin.com/in/karelkubias/)

    Organizations:
    CS Life Science Invest (https://lnkd.in/eyhWK7H)
    i&i Prague (https://www.linkedin.com/company/iniprague/)
    IOCB Tech (https://www.linkedin.com/company/iocb-tto-s-r-o-/)
    IOCB (https://www.linkedin.com/company/iocb-prague/)


    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    57 min
  • #24: How Young Scientist Are Trained Towards Entrepreneurship in Oxford

    Listen to my inspiring conversation with Vassilis Ragoussis about initiatives that support young scientists to become Entrepreneurs.

    We dived deep into the entrepreneurial Life Science Eco-System in Oxford, Europe, and the United States.

    If you want to know what the Eco-System in Oxford is doing for young scientist entrepreneurs, this podcast is for you.

    Learn more about Oxford University Biotech Society and Oxford Foundry.

    Vassilis is an avid networker and a Ph.D. student at the University of Oxford studying Clinical Medicine. His research requires to analyze large amounts of next-generation sequencing data using bioinformatics and computational analysis. In addition, he critically and objectively assesses his findings, validating any discoveries with functional experiments. During his time at Boston University and Oxford University, he competed at the highest level of rowing, dedicating 30+ hours a week to training and competing, gaining a profound understanding and tremendous respect for teamwork, time management, and team leadership. He has a strong interest in venture capital, life science consulting, and medical device innovations.

    Speaker:
    Christian Soschner
    Vassilis Ragoussis

    Organizations:
    CS Life Science Invest (https://lnkd.in/eyhWK7H)
    Oxford Foundry
    Oxford University Biotech Society
    University of Oxford

    Be part of our Network:
    Subscribe here:  https://mailchi.mp/e2467061ef75/lsg2g

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    57 min
  • #23: 40 Funds, One Series A. The Math of Funding a European Startup | Nicolaj Højer Nielsen

    Recorded in October 2020. The funding math still holds.

    Europe has the science. What it lacks is enough investors to fund it. Nicolaj Højer Nielsen did the count: an early-stage European biotech raising a 10 million euro Series A has roughly 40 to 50 realistic funds to pitch, and it needs three or four of them to say yes. In any other sales process, closing 10% of the entire market would be called a fantasy.

    Nicolaj is a serial entrepreneur and business angel who has been building startups since 1999. He left a pharma job in 2007, co-founded companies for equity, sold his first investment to Intel in 2015 and has invested full-time since. He wrote The Startup Funding Book, lectures on entrepreneurship at Copenhagen Business School and founded Copenhagen United, which backs early-stage software companies.

    In this episode:
    - Why an angel with 100,000 euros belongs in B2B (business-to-business) software, and why biotech takes closer to 500 million
    - Market risk versus technical risk, the core difference between software and therapeutics
    - InProTher's cancer approach, built on the 8% of the human genome left behind by ancient viral infections
    - Why an IPO (initial public offering) can block the exit most biotech assets need
    - The real bottleneck in Europe: scientists willing to give up a professorship to run a company
    - What he checks before the pitch deck: trust, track record and who vouches for you

    Chapters:
    (00:00) Introduction
    (00:32) From pharma employee to founder, and a first exit to Intel
    (04:10) Europe's startup ecosystem, 20 years ago and today
    (08:34) Why angels belong in B2B software
    (15:32) Market risk versus technical risk
    (18:21) The 500 million euro biotech portfolio
    (21:09) What Phase 2b data does for a deal with pharma
    (23:30) InProTher: cancer immunity from ancient viral DNA
    (28:56) Public funding and the valley of death
    (34:02) The real number of European biotech funds
    (39:49) IPO routes: Sweden's small-cap market
    (42:42) Why going public can kill your exit
    (45:42) The bottleneck: getting scientists out of academia
    (52:56) What he wants to see before the pitch deck
    (57:19) How startups land in the 25% that survive

    Guest links:
    Nicolaj Højer Nielsen: https://www.linkedin.com/in/nicolajnielsen/
    InProTher: https://www.linkedin.com/company/inprother/

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 1 min
  • #22: Irénée Robin: How Is China Managing the Coronavirus Situation in 2020?

    We are in the 7th month of the SARS-CoV-2 Pandemic in Europe.

    Governments are doing what’s necessary to deal with the situation.

    More and more governments are initiating strong measures to control the infection rate with SARS-CoV-2. Israel has announced a second lockdown from September 18 for about three weeks.

    There is a lot of coverage of European measures in the local news. Also, a lot of information is published about actions taken in the United States. I rarely read anything about the situation in Asia. Is life back to normal in Asia? How is the risk assessment of the novel Corona Virus in Asian countries?

    That‘s why I asked a colleague who lives in Shanghai and is one of the best experts in Life Science and Asia in the world. In this webinar/podcast recording, I will talk with Irénée Robins about these topics.

    Born in North-Eastern France in 1971, Irénée Robin has been living in China for almost 20 years. Married with three children, genuinely bicultural, he speaks, reads, and writes Mandarin fluently.

    After ten years in the financial services industry with the BNP Paribas group, Irénée started his life sciences career in 2003 by joining Shanghai Cathay Biotech, where he established his first Sino-foreign joint venture with a major German specialty chemicals conglomerate,
    leading to the creation of Degussa Cathay Biotechnology in Jining, Shandong Province.

    From 2006 to 2011, he worked with the Institut Pasteur of Shanghai, an international research venture established by the Chinese Academy of Sciences, the Shanghai municipal government, and Institut Pasteur. Under his tenure, the institute grew from 40 to 240 researchers, with numerous drug/vaccine discovery programs against life-threatening infectious diseases such as HFMD, HCV, and malaria. His efforts were directed at increasing the institute’s financial resources, notably via expanding CSR programs with multinational corporations and successfully applying to European and international grants.

    In 2012, as a Senior Representative for the Biotechnology Innovation Organization (BIO), he organized the “BIO Convention in China” in Shanghai.

    From 2013 to early 2019, he was the Chief Marketing Officer for Shanghai Newsummit Biopharma, a subsidiary of Shenzhen-listed Zhejiang Yatai Pharmaceuticals (SHE:002370). He attracted more than 30 Western companies onto the Chinese market during those six years through a vast array of transaction types, from in-licensing to co-development, distribution, and service agreements. He also established 4 Sino-foreign joint ventures in 4 different Chinese cities, including China’s most advanced molecular pathology and next-gen cancer diagnostics lab (Shanghai  German JV partner) and a first-in-class IVD development venture based on patients’ immune status markers, the use of NGS platforms. He targeted data mining/deep learning algorithms (Guangzhou – French JV partner).

    Speaker:
    Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
    Irénée Robin (https://www.linkedin.com/in/ireneerobin/)

    Companies:
    CS Life Science Invest (https://www.cslifescienceinvest.com/)
    VVR Medical (https://www.linkedin.com/company/vvr-international/)
    Be part of our Network:
    Subscribe here:  https://mailchi.mp/e2467061ef75/lsg2g


    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 59 min